S&P 500   4,690.80 (+0.09%)
DOW   35,663.68 (-0.16%)
QQQ   398.95 (+0.28%)
AAPL   174.56 (+1.97%)
MSFT   332.70 (-0.66%)
FB   331.09 (+2.56%)
GOOGL   2,945.59 (+0.01%)
AMZN   3,530.00 (+0.19%)
TSLA   1,063.50 (+1.12%)
NVDA   320.03 (-1.31%)
BABA   126.36 (+0.65%)
NIO   35.06 (+5.86%)
CGC   11.13 (+4.61%)
AMD   144.95 (+0.07%)
GE   98.59 (+1.07%)
MU   86.01 (+0.21%)
T   23.21 (+0.56%)
F   19.91 (-0.25%)
DIS   153.35 (+1.68%)
PFE   51.29 (-0.83%)
AMC   33.00 (+6.31%)
ACB   6.71 (+5.17%)
BA   211.72 (+1.38%)
S&P 500   4,690.80 (+0.09%)
DOW   35,663.68 (-0.16%)
QQQ   398.95 (+0.28%)
AAPL   174.56 (+1.97%)
MSFT   332.70 (-0.66%)
FB   331.09 (+2.56%)
GOOGL   2,945.59 (+0.01%)
AMZN   3,530.00 (+0.19%)
TSLA   1,063.50 (+1.12%)
NVDA   320.03 (-1.31%)
BABA   126.36 (+0.65%)
NIO   35.06 (+5.86%)
CGC   11.13 (+4.61%)
AMD   144.95 (+0.07%)
GE   98.59 (+1.07%)
MU   86.01 (+0.21%)
T   23.21 (+0.56%)
F   19.91 (-0.25%)
DIS   153.35 (+1.68%)
PFE   51.29 (-0.83%)
AMC   33.00 (+6.31%)
ACB   6.71 (+5.17%)
BA   211.72 (+1.38%)
S&P 500   4,690.80 (+0.09%)
DOW   35,663.68 (-0.16%)
QQQ   398.95 (+0.28%)
AAPL   174.56 (+1.97%)
MSFT   332.70 (-0.66%)
FB   331.09 (+2.56%)
GOOGL   2,945.59 (+0.01%)
AMZN   3,530.00 (+0.19%)
TSLA   1,063.50 (+1.12%)
NVDA   320.03 (-1.31%)
BABA   126.36 (+0.65%)
NIO   35.06 (+5.86%)
CGC   11.13 (+4.61%)
AMD   144.95 (+0.07%)
GE   98.59 (+1.07%)
MU   86.01 (+0.21%)
T   23.21 (+0.56%)
F   19.91 (-0.25%)
DIS   153.35 (+1.68%)
PFE   51.29 (-0.83%)
AMC   33.00 (+6.31%)
ACB   6.71 (+5.17%)
BA   211.72 (+1.38%)
S&P 500   4,690.80 (+0.09%)
DOW   35,663.68 (-0.16%)
QQQ   398.95 (+0.28%)
AAPL   174.56 (+1.97%)
MSFT   332.70 (-0.66%)
FB   331.09 (+2.56%)
GOOGL   2,945.59 (+0.01%)
AMZN   3,530.00 (+0.19%)
TSLA   1,063.50 (+1.12%)
NVDA   320.03 (-1.31%)
BABA   126.36 (+0.65%)
NIO   35.06 (+5.86%)
CGC   11.13 (+4.61%)
AMD   144.95 (+0.07%)
GE   98.59 (+1.07%)
MU   86.01 (+0.21%)
T   23.21 (+0.56%)
F   19.91 (-0.25%)
DIS   153.35 (+1.68%)
PFE   51.29 (-0.83%)
AMC   33.00 (+6.31%)
ACB   6.71 (+5.17%)
BA   211.72 (+1.38%)
NASDAQ:CLGN

CollPlant Biotechnologies Stock Forecast, Price & News

$16.88
+0.32 (+1.93%)
(As of 12/8/2021 11:20 AM ET)
Add
Compare
Today's Range
$16.82
$16.88
50-Day Range
$15.00
$22.48
52-Week Range
$8.19
$24.26
Volume
220 shs
Average Volume
64,569 shs
Market Capitalization
$95.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.


CollPlant Biotechnologies logo

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. It's products include VergenixSTR, VergenixFG, and CollPlant Surgical Matrix. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

Headlines

CGTS MONDAY: MJC PORTFOLIO UP 7% TODAY
November 1, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLGN
Employees
53
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.14 million
Book Value
$8.55 per share

Profitability

Net Income
$-5.77 million
Pretax Margin
6.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$95.71 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/18/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/25/2022

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

781st out of 1,394 stocks

Surgical Appliances & Supplies Industry

18th out of 27 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -












CollPlant Biotechnologies (NASDAQ:CLGN) Frequently Asked Questions

Is CollPlant Biotechnologies a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CollPlant Biotechnologies stock.
View analyst ratings for CollPlant Biotechnologies
or view top-rated stocks.

How has CollPlant Biotechnologies' stock been impacted by COVID-19?

CollPlant Biotechnologies' stock was trading at $10.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLGN shares have increased by 65.5% and is now trading at $16.88.
View which stocks have been most impacted by COVID-19
.

Are investors shorting CollPlant Biotechnologies?

CollPlant Biotechnologies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 14,600 shares, an increase of 24.8% from the October 31st total of 11,700 shares. Based on an average daily volume of 33,400 shares, the short-interest ratio is currently 0.4 days. Currently, 0.2% of the shares of the company are short sold.
View CollPlant Biotechnologies' Short Interest
.

When is CollPlant Biotechnologies' next earnings date?

CollPlant Biotechnologies is scheduled to release its next quarterly earnings announcement on Friday, March 25th 2022.
View our earnings forecast for CollPlant Biotechnologies
.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) released its quarterly earnings data on Thursday, November, 18th. The company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.01. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.25 million. CollPlant Biotechnologies had a trailing twelve-month return on equity of 2.89% and a net margin of 6.95%.
View CollPlant Biotechnologies' earnings history
.

What price target have analysts set for CLGN?

1 equities research analysts have issued twelve-month price targets for CollPlant Biotechnologies' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate CollPlant Biotechnologies' share price to reach $26.00 in the next year. This suggests a possible upside of 54.0% from the stock's current price.
View analysts' price targets for CollPlant Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are CollPlant Biotechnologies' key executives?

CollPlant Biotechnologies' management team includes the following people:
  • Yehiel Tal, Chief Executive Officer
  • Ilana Belzar, Chief Operating Officer
  • Eran Rotem, Chief Financial Officer & Deputy CEO
  • Oded Shoseyov, Chief Scientist
  • Nadav Orr, Vice President-Research & Development

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and (PRMW).

When did CollPlant Biotechnologies IPO?

(CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

What is CollPlant Biotechnologies' stock symbol?

CollPlant Biotechnologies trades on the NASDAQ under the ticker symbol "CLGN."

Who are CollPlant Biotechnologies' major shareholders?

CollPlant Biotechnologies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Investment Management of Virginia LLC (10.07%), Villere ST Denis J & Co. LLC (4.38%), Benjamin F. Edwards & Company Inc. (1.02%), Sigma Planning Corp (0.33%), Renaissance Technologies LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%).

Which major investors are selling CollPlant Biotechnologies stock?

CLGN stock was sold by a variety of institutional investors in the last quarter, including Benjamin F. Edwards & Company Inc..

Which major investors are buying CollPlant Biotechnologies stock?

CLGN stock was bought by a variety of institutional investors in the last quarter, including Investment Management of Virginia LLC, Sigma Planning Corp, Renaissance Technologies LLC, and Villere ST Denis J & Co. LLC.

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CollPlant Biotechnologies' stock price today?

One share of CLGN stock can currently be purchased for approximately $16.88.

How much money does CollPlant Biotechnologies make?

CollPlant Biotechnologies has a market capitalization of $95.71 million and generates $6.14 million in revenue each year. The company earns $-5.77 million in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does CollPlant Biotechnologies have?

CollPlant Biotechnologies employs 53 workers across the globe.

What is CollPlant Biotechnologies' official website?

The official website for CollPlant Biotechnologies is www.collplant.com.

Where are CollPlant Biotechnologies' headquarters?

CollPlant Biotechnologies is headquartered at 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140.

How can I contact CollPlant Biotechnologies?

CollPlant Biotechnologies' mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company can be reached via phone at 972732325600, via email at [email protected], or via fax at 972-73-232-5602.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.